The medical research future fund has taken financial stakes and negotiated returns on investments from assisting in the development of promising drugs that could likely have returns or royalties paid to the government which can then be reinvested in further research etc. The Cooperative Research Centres program, where the government partners with pharmaceutical companies co-fund research projects where the gov benefits financially rather than simply handing out money. Should be mandated that whereby if all avenues for private investment have been exhausted, the gov must step in if it is clear there is a drug that provides better outcomes for patents and particularly avoid horrible side effects etc, they must step in and use those mechanisms to make it happen.
- Forums
- ASX - By Stock
- SPL
- When multiple potential partners say yeah nah, not interested.
When multiple potential partners say yeah nah, not interested., page-32
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
Add SPL (ASX) to my watchlist
|
|||||
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.29M |
Open | High | Low | Value | Volume |
10.0¢ | 10.5¢ | 10.0¢ | $12.03K | 116.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3000 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 109616 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 128702 | 0.098 |
1 | 6185 | 0.097 |
3 | 35417 | 0.096 |
4 | 602490 | 0.095 |
2 | 30000 | 0.094 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 105000 | 2 |
0.110 | 114609 | 7 |
0.115 | 68531 | 5 |
0.120 | 89055 | 5 |
0.125 | 281784 | 3 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |